Achieving Bioavailability Enhancement for Poorly Soluble Compounds

Life Sciences, Pharmaceutical, Pharma Manufacturing & Supply Chain,
  • Friday, April 30, 2021 | 11am EDT (NA) / 4pm BST (UK) / 5pm CEST (EU-Central)
  • 60 min

A large and increasing fraction of orally administered small molecules in pharma company pipelines have poor oral absorption due to low aqueous solubility or dissolution rate. To address this trend, evaluating formulation approaches for increasing oral bioavailability are becoming routine early on in formulation development programs. Selecting the appropriate technology for your compound requires careful consideration of the compound physicochemical properties, target dose and pharmacokinetic profile, as well as overall market image. Understanding the root cause for poor exposure driven by the key barriers to absorption for a given compound can drastically reduce the time and effort spent on selecting and progressing multiple technologies.

Register for this webinar to learn about a general overview of some of the most common bioavailability-enhancing technologies for poorly soluble compounds and a strategic framework for identifying and selecting the appropriate technology. A case study demonstrating the approach will be presented for a poorly soluble BCS Class II compound.



Aaron Stewart, Associate Principal Scientist, Lonza Pharma and Biotech

Aaron Stewart is an Associate Principal Scientist at Lonza in Bend, Oregon. He works on internal research and development initiatives to support global product development. His primary areas of expertise are in amorphous dispersion formulation development with an emphasis on in vitro testing models and design, absorption modeling and pharmacokinetics. Aaron has been with the company since 2011. He graduated with a M.S in chemistry from the University of Oregon.

Message Presenter

Who Should Attend?

  • Pharmaceutical Scientists
  • Engineers in Formulation Development
  • Academia
  • Consultants

What You Will Learn

The audience will learn how to select an appropriate technology for bioavailability enhancement through careful consideration of the compound’s physicochemical properties, dose and target pharmacokinetic profile, using a streamlined approach to bioavailability-enhanced formulation development.

Xtalks Partner

Lonza Pharma & Biotech

At Lonza Pharma & Biotech, we provide development and manufacturing services that enable biopharma companies to bring small molecule medicines to patients in need.

From drug substance to the final drug product, our solutions feature enabling technologies to successful advance your molecule, and concept to commercial services to simplify your outsourcing experience. Our extensive track record includes development and manufacture across a wide range of drug substances, particle-engineered intermediates and specialized drug products for oral solid, parenteral and inhaled delivery routes. We continuously invest to solve not just current, but also future challenges that support the development and commercialization of pioneering therapies.

Together, we can bring your next medicine to life.

Media Partner

The original site for employees in the pharma, medical, diagnostic and related industries.  Our hand-curated daily news feed and active message forums will keep you informed.

You Must Login To Register for this Free Webinar

Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.

Create Account